Selective Estrogen Receptor Modulators for Women of Child-bearing Age With Schizophrenia
Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
The aim of the project is to investigate the use of Raloxifene (a new form of estrogen) in
the treatment of young women with schizophrenia and schizoaffective disorder. Raloxifene is a
Selective Estrogen Receptor Modulator (SERM),which means that it can affect the central
nervous system (CNS) effects of estrogen (eg. improving emotional symptoms, memory,
information processing and concentration), without adversely affecting reproductive
tissue/organs such as breast, uterus and ovaries. The investigators are conducting a
double-blind, placebo controlled, three month study comparing the psychotic symptom response
of women with schizophrenia in both groups. One group will receive standard antipsychotic
medication plus 120mg Raloxifene, while the second group will receive standard antipsychotic
medication plus oral placebo.